Abstract: A method of preparing a compound of Formula (I) comprising reacting the compound of Formula (A) with a base and a compound of Formula (B) to yield a compound of Formula (C).

Abstract: The present invention discloses compounds that are useful in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD)

Abstract: The present invention pertains to a vaccine comprising an IgM protease antigen of Streptococcus suis, for use in a method for protecting pigs against an infection with Streptococcus suis of serotype 2 and against an infection with Streptococcus suis of serotype 9.

Abstract: The present invention pertains to a vaccine comprising (a) an immunologically effective amount of a Streptococcus suis IgM protease antigen, (b) an immunologically effective amount of an Escherichiacoli fibmrial antigen, and (c) an immunologically effective amount of a Clostridium toxoid, and also pertains to use of the vaccine in a method for protecting pigs against a pathogenic infection with Streptococcus suis, Escherichia coli and Clostridium.

Abstract: The present invention provides caninized human anti-human IL-4R? antibodies that have specific sequences and a high binding affinity for canine IL-4R?. The invention also relates to use of these antibodies in the treatment of dogs against atopic dermatitis.

Abstract: A process for the manufacture of semi-plastic pharmaceutical unit doses using a rotary moulding machine and semi-plastic pharmaceutical dosage units obtained by this process.

Abstract: The present invention pertains to a vaccine comprising an ORF2 encoded protein of porcine circo virus 2 (PCV2) and a pharmaceutically acceptable carrier, for use in a method to protect a pig against an infection with porcine circo virus type 2 by administering the vaccine to the pig, wherein the vaccine comprises less than 20 ?g per dose of the ORF2 encoded protein, the protein being of a porcine circo virus of genotype 2b.

Abstract: An animal health monitoring system includes a plurality of animal tag assemblies configured for being disposed on members of an animal population, each of the animal tag assemblies including one or more sensors configured to measure one or more animal characteristics of a member of the animal population. The system includes a concentrator communicatively coupled to the plurality of animal tag assemblies and configured to acquire one or more animal characteristics from the plurality of animal tag assemblies. The system includes a controller communicatively coupled to the concentrator and configured to receive the acquired one or more animal characteristics from the plurality of animal tag assemblies from the concentrator, determine a health state of one or more of the members of the animal population based on the received one or more animal characteristics and report the determined health state to one or more user devices.

Abstract: The present invention relates to a combination vaccine for swine, comprising non-replicating antigen from porcine circovirus type 2 (PCV2), and live porcine reproductive and respiratory syndrome virus (PRRSV); the combination vaccine is formulated as an oil-in-water emulsion, and is adjuvated with squalane and vitamin E-acetate. This combination vaccine was found to be immunologically effective against all pathogens: PCV2, and PRRSV.

Abstract: An injectable pharmaceutical composition comprising an isoxazoline compound of Formula (I) or a salt or N-oxide thereof wherein the isoxazoline compound has a particle size of from about 25 microns to about 250 microns and a method of preventing or treating a parasite infestation using the same.

Abstract: A solid oral pharmaceutical composition for delivery of a pharmaceutically acceptable active ingredient to an animal where the composition comprises an isoxazoline compound, a solvent and an excipient, a process for the manufacture of such solid oral pharmaceutical composition and a method of controlling a parasite infection administering such solid oral pharmaceutical composition.

Abstract: The present invention provides a vaccine for feline leukemia virus and methods of making and using the vaccine alone, or in combinations with other protective agents.

Abstract: The present invention discloses compounds of formula (I) that are useful in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).

Abstract: The present invention relates to the use of a diluent for the in-use stabilisation of cells infected with a cell-associated alphaherpesvims. Contrary to the long-standing practice of incorporating a considerable amount of peptone into the diluent for such virus-infected cells, it was found that a reduction of the amount of protein in the diluent improved the in-use stability of alphaherpesvirus-infected cells. Whereby the best stability was even obtained using a protein-free diluent. This effect was especially pronounced for recombinant HVT viruses expressing a heterologous insert. Being protein-free is highly advantageous for the production of the diluent, in respect of costs, safety, and consistency of production.

Abstract: An implant for the control of parasites in livestock comprising an isoxazoline compound of Formula (I) or salt or solvate thereof, wherein the implant comprises one or more pellets each of which comprises the isoxaxoline compound and a pharmaceutically acceptable excipient and a method of preventing or treating a parasite infestation using the same.

Abstract: An animal health monitoring system includes a plurality of animal tag assemblies configured for being disposed on members of an animal population, each of the animal tag assemblies including one or more sensors configured to measure one or more animal characteristics of a member of the animal population. The system includes a concentrator communicatively coupled to the plurality of animal tag assemblies and configured to acquire one or more animal characteristics from the plurality of animal tag assemblies. The system includes a controller communicatively coupled to the concentrator and configured to receive the acquired one or more animal characteristics from the plurality of animal tag assemblies from the concentrator, determine a health state of one or more of the members of the animal population based on the received one or more animal characteristics, and report the determined health state to one or more user devices.

Abstract: The present invention is directed to a salt of a compound of formula (I), R1 is halogen or methyl; X is methyl, OR2, or SR2; Y1, Y2 is CR3 or N, and one of Y1, Y2 is N and one of Y1, Y2 is CR3; R2 is methyl or ethyl; R3 is hydrogen or methyl, wherein the salt is chosen from the group 10 consisting of malate salt, citrate salt, tartrate salt, oxalate salt, fumarate salt, lactate salt, glucoronate salt, oxoglucoronate salt, ethanesulfonate salt, and succinate salt. The present invention is further related to a pharmaceutical formulation comprising the salt of the invention wherein the base compound is present in an amount of 2-30% (w/v) and having a pH value of at least 3.7 and to methods of treatment using the salt of the invention.

Abstract: A process for the manufacture of semi-plastic pharmaceutical unit doses using a rotary moulding machine and semi-plastic pharmaceutical dosage units obtained by this process.

Abstract: The present invention relates to a novel porcine pestivirus, to proteins of the virus and to vaccines based upon the virus and proteins thereof. The invention also relates to DNA fragments comprising a gene of the virus and to DNA vaccines based upon genes of the virus. Furthermore the invention relates to antibodies that are reactive with the novel virus and to diagnostic tests for the detection of the virus or antibodies against the virus.

Abstract: The present invention pertains to a vaccine for use in prophylactically treating an animal against an infection with porcine circovirus type 2 (PCV2) and an infection with PRRS virus, the vaccine comprising in combination non-replicating immunogen of porcine circovirus type 2 and live attenuated PRRS virus, wherein the vaccine additionally comprises albumin.